Skip to main content

Invega Sustenna FDA Approval History

Last updated by Judith Stewart, BPharm on March 2, 2021.

FDA Approved: Yes (First approved July 31, 2009)
Brand name: Invega Sustenna
Generic name: paliperidone palmitate
Dosage form: Extended-Release Injectable Suspension
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Schizophrenia, Schizoaffective Disorder

Invega Sustenna (1-month paliperidone palmitate) is a long-acting injectable atypical antipsychotic indicated for the treatment of schizophrenia and schizoaffective disorder.

Development timeline for Invega Sustenna

Nov 13, 2014Approval FDA Approves sNDA for Invega Sustenna (paliperidone palmitate) for Schizoaffective Disorder
Aug  3, 2009Approval FDA Approves Invega Sustenna for the Acute and Maintenance Treatment of Schizophrenia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.